Who should receive combination therapy for ER positive breast cancer?

Bookmark and Share
Published: 12 Oct 2016
Views: 1428
Rating:
Save
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

Dr Gnant speaks with ecancertv at ESMO 2016, reviewing the conference controversy session: Should combined endocrine therapy with targeted agents now be the standard of care for ER metastatic breast cancer?

Weighing cost and safety profile, Dr Gnant thinks further specificity in patient subtypes may streamline treatment selection.

He references the FALCON trial, which has demonstrated the superiority of fulvestrant over anastrazole, as illustrative of the problem in finding preferred combinations when one component may no longer be the best available.